Niagen Bioscience, Inc. Common Stock NAGE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $130.42M+20.8% | $129.42M+29.9% | $124.71M+36.0% | $116.3M+35.9% | $107.93M+29.8% | ||
| $46.58M+15.1% | $46.23M+21.6% | $45.03M+27.4% | $42.31M+26.2% | $40.46M+24.7% | ||
| $83.83M+24.3% | $83.19M+35.1% | $79.68M+41.5% | $73.99M+42.1% | $67.46M+33.0% | ||
| 64.3%+1.8pp | 64.3%+2.4pp | 63.9%+2.4pp | 63.6%+2.8pp | 62.5%+1.5pp | ||
| $6.55M+26.5% | $6.33M+5.2% | $5.94M+1.3% | $5.43M-6.6% | $5.18M-11.6% | ||
| $37.06M+20.2% | $35.51M+20.5% | $33.81M+24.0% | $32.08M+22.2% | $30.85M+21.9% | ||
| $29.12M+59.9% | $27.06M+47.2% | $20.64M-9.3% | $19.81M-11.1% | $18.21M-23.9% | ||
| $70.75M+30.5% | $66.91M+24.2% | $60.38M+8.1% | $57.32M+5.5% | $54.23M-1.5% | ||
| $13.08M-1.1% | $16.28M+111% | $19.3M+4,219% | $16.67M+824% | $13.23M+403% | ||
| 10%-2.2pp | 12.6%+4.8pp | 15.5%+15.0pp | 14.3%+17.0pp | 12.3%+17.5pp | ||
| $1.83M+35.6% | $1.91M+69.4% | $1.95M+87.7% | $1.66M+74.7% | $1.35M+61.8% | ||
| —— | $2.13M+88.4% | $1.88M— | $1.63M— | $1.38M— | ||
| —— | —— | —— | —— | —— | ||
| $19.7M+35.1% | $18.19M+105% | $21.25M+15,469% | $18.33M+716% | $14.58M+447% | ||
| $1.06M+124% | $810K+166% | $823K— | $601K— | $473K— | ||
| $18.64M+32.1% | $17.38M+103% | $20.43M+1,390% | $17.73M+1,309% | $14.11M+487% | ||
| 14.3%+1.2pp | 13.4%+4.8pp | 16.4%+14.9pp | 15.2%+17.0pp | 13.1%+17.4pp | ||
| $0.21+23.5% | $0.20+100% | $0.24+2,300% | $0.21+1,150% | $0.17+440% | ||
| $0.24+33.3% | $0.23+130% | $0.27+2,600% | $0.23+1,250% | $0.18+460% | ||
| 342.9M+9.0% | 341.5M+11.4% | 334.2M+10.1% | 325.4M+8.2% | 314.7M+4.8% | ||
| 318.1M+4.2% | 316M+4.4% | 312.8M+3.7% | 309M+2.7% | 305.3M+1.7% | ||
| —— | $1.98M— | $1.49M— | $991.5K— | $495.75K— | ||
| $1.83M+35.6% | $1.91M+69.4% | $1.95M+87.7% | $1.66M+74.7% | $1.35M+61.8% | ||
| —— | -$214K— | -$160.5K— | -$107K— | -$53.5K— | ||
| —— | —— | —— | —— | —— | ||
| $13.08M-1.1% | $16.28M+111% | $19.3M+4,219% | $16.67M+824% | $13.23M+403% | ||
| $13.96M-0.4% | $17.06M+99.8% | $20.08M+1,459% | $17.45M+1,355% | $14.02M+514% | ||
| $13.96M-0.4% | $17.06M+99.8% | $20.08M+1,459% | $17.45M+1,355% | $14.02M+514% | ||
| 10.7%-2.3pp | 13.2%+4.6pp | 16.1%+14.7pp | 15%+16.6pp | 13%+17.1pp | ||
| $13.08M-1.1% | $16.28M+111% | $19.3M+4,219% | $16.67M+824% | $13.23M+403% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Niagen Bioscience, Inc. Common Stock's revenue?
- Niagen Bioscience, Inc. Common Stock (NAGE) generated $130.4M in revenue over the trailing twelve months, up 20.8% year over year.
- Is Niagen Bioscience, Inc. Common Stock profitable?
- Niagen Bioscience, Inc. Common Stock reported $18.6M in net income over the trailing twelve months, a 14.3% net margin.
- What are Niagen Bioscience, Inc. Common Stock's profit margins?
- Gross margin is 64.3% and operating margin is 10.0%, with a 14.3% net margin.
- What is Niagen Bioscience, Inc. Common Stock's earnings per share?
- Niagen Bioscience, Inc. Common Stock's diluted EPS over the trailing twelve months is $0.21.
- Where does Niagen Bioscience, Inc. Common Stock's income statement data come from?
- Every line is extracted from Niagen Bioscience, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
